Abstract

Simple SummaryAstrocytomas are the most common type of primary brain tumor in adults. In this study, 64 astrocytoma samples of grades II–IV were analyzed for genetic and epigenetic changes as well as protein expression patterns in order to explore the roles of the Wnt pathway components, such as DKK1, DKK3, GSK3β, β-catenin, and APC in astrocytoma initiation and progression. Our findings on DKK1 and DKK3 show the importance of methylation in the regulation of Wnt signaling activity and also indicate pro-oncogenic effects of GSK3β on astrocytoma development and progression. Close connections between large deletions and mutations in the APC gene and increased β-catenin expression in glioblastoma were also established. Our results suggest that Wnt pathway related genes and proteins play an active role in the etiology of astrocytic brain tumors.In the present study, we investigated genetic and epigenetic changes and protein expression levels of negative regulators of Wnt signaling, DKK1, DKK3, and APC as well as glycogen synthase kinase 3 (GSK3β) and β-catenin in 64 human astrocytomas of grades II–IV. Methylation-specific PCR revealed promoter methylation of DKK1, DKK3, and GSK3β in 38%, 43%, and 18% of samples, respectively. Grade IV comprised the lowest number of methylated GSK3β cases and highest of DKK3. Evaluation of the immunostaining using H-score was performed for β-catenin, both total and unphosphorylated (active) forms. Additionally, active (pY216) and inactive (pS9) forms of GSK3β protein were also analyzed. Spearman’s correlation confirmed the prevalence of β-catenin’s active form (rs = 0.634, p < 0.001) in astrocytoma tumor cells. The Wilcoxon test revealed that astrocytoma with higher levels of the active pGSK3β-Y216 form had lower expression levels of its inactive form (p < 0.0001, Z = −5.332). Changes in APC’s exon 11 were observed in 44.44% of samples by PCR/RFLP. Astrocytomas with changes of APC had higher H-score values of total β-catenin compared to the group without genetic changes (t = −2.264, p = 0.038). Furthermore, a positive correlation between samples with methylated DKK3 promoter and the expression of active pGSK3β-Y216 (rs = 0.356, p = 0.011) was established. Our results emphasize the importance of methylation for the regulation of Wnt signaling. Large deletions of the APC gene associated with increased β-catenin levels, together with oncogenic effects of both β-catenin and GSK3β, are clearly involved in astrocytoma evolution. Our findings contribute to a better understanding of the etiology of gliomas. Further studies should elucidate the clinical and therapeutic relevance of the observed molecular alterations.

Highlights

  • Astrocytomas are glial cell tumors originating from astrocytes and account for nearly half of all primary brain tumors

  • Out of 50 analyzed astrocytoma samples of different grades, 41 (82%) had an unmethylated GSK3β gene promoter, while methylation of the promoter region was detected in nine samples (18%), including three AII (30%), three AIII (27%), and three GBM (10.34%) (Figure 3A)

  • It was obvious that grade IV comprised the lowest number of methylated cases for GSK3β and highest for DKK3, the Kruskal-Wallis test showed no significant association of methylation patterns of GSK3β (p = 0.235), DKK1 (p = 0.771), and DKK3 (p = 0.723) promoter regions with the tumor malignancy grade

Read more

Summary

Introduction

Astrocytomas are glial cell tumors originating from astrocytes and account for nearly half of all primary brain tumors. The proliferative potential of diffuse astrocytomas and their growth rate are much lower than those of GBMs, which are a highly aggressive tumor with pronounced brain invasion and fast progression [1]. In addition to the biological behavior, an important criterion for the classification of diffuse glioma is the status of IDH1 and IDH2 gene mutations; astrocytomas are defined as IDH mutant or IDH wild-type. Low-grade astrocytomas and secondary GBMs often carry IDH mutations, associated with younger age, as well as a much better prognosis [3,4]. IDH wild-type status refers to 90% of GBMs and indicates a primary tumor that arises de novo and carries a poorer prognosis than those classified as IDH mutant

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call